Literature DB >> 8944059

Kinetic analysis of recurrence and survival after potentially curative resection of nonsmall cell lung cancer.

T Mitsudomi1, K Nishioka, R Maruyama, G Saitoh, M Hamatake, Y Fukuyama, H Yaita, T Ishida, K Sugimachi.   

Abstract

BACKGROUND: About two-thirds of the patients with nonsmall cell lung cancer (NSCLC) who undergo a potentially curative resection eventually suffer from recurrent disease. However, it has yet to be elucidated as to how survival after recurrence is influenced by different variables, including timing, type of recurrence, or other clinicopathological features. There have been few studies concentrating on the kinetics of growth of occult micrometastatic tumor cells that eventually manifest as tumor recurrence.
METHODS: We retrospectively reviewed the charts of 197 patients who developed recurrence after a potentially curative resection for NSCLC.
RESULTS: The median disease-free interval was a little over 1 year (395 days), as was the median postrecurrence survival-383 days. We created a model for the kinetics of recurrence by assuming that: (1) a tumor of 10(9) cells is the usual limit of detection, (2) patients generally die before the tumor reaches 10(12) cells, and (3) it takes 1 year for average lung cancer cells to show a 10-fold increase. The model indicated that as much as 10(9) tumor cells should have been present immediately after the operation. Alternatively, the residual tumor cells should have an accelerated growth after the surgery.
CONCLUSIONS: These models indicate the importance of developing a sensitive detection method for occult metastatic cells and to understand the tumor dormancy mechanism.

Entities:  

Mesh:

Year:  1996        PMID: 8944059     DOI: 10.1002/(SICI)1096-9098(199611)63:3<159::AID-JSO5>3.0.CO;2-C

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  5 in total

1.  Rib metastasis appearing 8 years after surgery for lung cancer: report of a case.

Authors:  S Kase; K Sugio; T Yano; K Nishioka; K Yamazaki; T Okamoto; T Koga; M Yamaguchi; K Ondo; K Sugimachi
Journal:  Surg Today       Date:  2000       Impact factor: 2.549

2.  Inhibition of urokinase plasminogen activator with a novel enzyme inhibitor, WXC-340, ameliorates endotoxin and surgery-accelerated growth of murine metastases.

Authors:  S D Killeen; E J Andrews; J H Wang; T Wu; W Schmalix; B Muehlenweg; H P Redmond
Journal:  Br J Cancer       Date:  2007-01-29       Impact factor: 7.640

3.  Prognostic significance of the combined score of endothelial expression of nucleolin and CD31 in surgically resected non-small cell lung cancer.

Authors:  Hongyun Zhao; Yan Huang; Cong Xue; Yang Chen; Xue Hou; Ying Guo; Liping Zhao; Zhi huang Hu; Yujie Huang; Yongzhang Luo; Li Zhang
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

4.  Effects of Surgery and Chemotherapy on Metastatic Progression of Prostate Cancer: Evidence from the Natural History of the Disease Reconstructed through Mathematical Modeling.

Authors:  Leonid Hanin; Marco Zaider
Journal:  Cancers (Basel)       Date:  2011-09-20       Impact factor: 6.639

5.  Prognosis of recurrent non-small cell lung cancer following complete resection.

Authors:  Hidefumi Sasaki; Ayumi Suzuki; Tsutomu Tatematsu; Masayuki Shitara; Yu Hikosaka; Katsuhiro Okuda; Satoru Moriyama; Motoki Yano; Yoshitaka Fujii
Journal:  Oncol Lett       Date:  2014-02-07       Impact factor: 2.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.